Epigral Ltd (EPIGRAL) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Epigral Ltd. reported strong performance in Q3 FY25, driven by volume growth and a diversified revenue model.
- The company achieved 37% revenue growth for the nine months of FY25, with a 15% increase in sales volume, primarily from the Derivatives business.
- Domestic demand outperformed the global market.
- New projects and a focus on value-added import substitute products contributed to consistent growth.
- The Derivatives business now accounts for 54% of revenue for the nine months of FY25, up from 44% in the same period last year.
- Capacity expansions in previous years fueled volume growth and are expected to contribute further in FY26, along with the chlorotoluene value chain project, which is expected to be commissioned in the current quarter.
- The company announced plans to double its CPVC resin capacity from 75,000 tonnes per annum to 150,000 tonnes per annum and Epichlorohydrin capacity from 50,000 tonnes per annum to 100,000 tonnes per annum. These expansions are expected to be commissioned in the first half of FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.